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Persistent Inhibition of Neointimal Hyperplasia After
Sirolimus-Eluting Stent Implantation
Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular
Ultrasound Follow-Up
Muzaffer Degertekin, MD; Patrick W. Serruys, MD, PhD; David P. Foley, MB, MRCPI, PhD;
Kengo Tanabe, MD; Evelyn Regar, MD; Jeroen Vos, MD, PhD; Peter C. Smits, MD, PhD;
Wim J. van der Giessen, MD, PhD; Marcel van den Brand, MD, PhD;
Pim de Feyter, MD, PhD; Jeffrey J. Popma, MD
Background—Early results of sirolimus-eluting stent implantation showed a nearly complete abolition of neointimal
hyperplasia. The question remains, however, whether the early promising results will still be evident at long-term
follow-up. The objective of our study was to evaluate the efficiency of sirolimus-eluting stent implantation for up to 2
years of follow-up.
Methods and Results—Fifteen patients with de novo coronary artery disease were treated with 18-mm sirolimus-eluting
Bx-Velocity stents (Cordis) loaded with 140 g sirolimus/cm2 metal surface area in a slow release formulation.
Quantitative angiography (QCA) and intravascular ultrasound (IVUS) were performed according to standard protocol.
Sirolimus-eluting stent implantation was successful in all 15 patients. During the in-hospital course, 1 patient died of
cerebral hemorrhage after periprocedural administration of abciximab, and 1 patient underwent repeat stenting after 2
hours because of edge dissection that led to acute occlusion. Through 6 months and up to 2 years of follow-up, no
additional events occurred. QCA analysis revealed no significant change in stent minimal lumen diameter or percent
diameter stenosis, and 3-dimensional IVUS showed no significant deterioration in lumen volume. In 2 patients,
additional stenting was performed because of significant lesion progression remote from the sirolimus-eluting stent.
Conclusion—Sirolimus-eluting stents showed persistent inhibition of neointimal hyperplasia for up to 2 years of follow-up.
(Circulation. 2002;106:1610-1613.)
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Coronary stents provide a mechanical scaffolding thatvirtually eliminates recoil and remodeling, but they do
not reduce neointimal growth. Sirolimus-eluting stents may
provide a definitive solution for in-stent restenosis in the
short term.1,2,3 Histological follow-up in the porcine model,
however has indicated that late neointimal hyperplasia can
recur at 90 and 180 days (Andrew J. Carter, DO, unpublished
data, 2001). Thus, there are sufficient concerns about delayed
healing with consequent risks of late restenosis4 and throm-
bosis,5 late malapposition,6 edge effect,7 and, on the other
hand, delayed restenosis,8 to warrant additional late follow-up
catheterization. The objective of this study was to determine
angiographic, intravascular ultrasound (IVUS), and clinical
outcome up to 2 years after implantation of sirolimus-eluting
stents in de novo coronary lesions.
Methods
Patients and Stent Implantation
The patient population consisted of 15 patients who were included at
our center between February and May of 2000 in the First in Man
clinical trial on sirolimus-eluting stents (FIM). The methodology has
been published previously.3
In brief, patients with short (15 mm) de novo coronary lesions
received a single 18-mm sirolimus-eluting Bx-Velocity stent (Cor-
dis). All lesions were predilated before stent implantation. The
sirolimus coating was a slow-release formulation (28-day drug
release with 140 g of sirolimus per cm2 stent surface area). All
patients received aspirin (325 mg/d, indefinitely) and clopidogrel
(300 mg loading dose immediately and 75 mg/d for 8 weeks).
Angiographic and IVUS Analysis
Serial coronary angiography was performed at baseline, 6 months,
and late follow-up (mean 20.32.4; range 18 to 24 months). Two
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coronary segments were subjected to quantitative angiography
(QCA), one in stent and one in lesion. The in-stent segment
encompassed only the 18-mm segment covered by the stent. The
in-lesion segment was defined as the stent plus 5 mm proximal and
5 mm distal to the edge or the nearest side branch. In-stent and
in-lesion stenosis was defined as 50% diameter stenosis. QCA
analysis was done by an independent core laboratory (Brigham and
Women’s Hospital, Boston, Mass).
Stented vessel segments were examined with mechanical IVUS,
using automated pullback at 0.5 mm per second. A coronary segment
beginning 5 mm distal to and extending 5 mm proximal to the stented
segment was also examined. A computer-based contour detection
program was used for automated 3-dimensional reconstruction of the
stented segment from up to 200 cross-sectional images.9
Clinical Follow-Up
We assessed the clinical outcome during the hospital stay, at 6
months, and up to 2 years later. Major adverse cardiac events were
defined as death, acute myocardial infarction, and repeat revascular-
ization of the target lesion and/or vessel by coronary artery bypass
graft or percutaneous coronary intervention.
Statistical Analysis
Quantitative data are presented as meanSD. Multiple comparisons
between postprocedural 6- and 20-month follow-up measurements
were performed by ANOVA. Paired comparisons were performed by
Student’s t test.
Results
Six-month outcomes of the original 15 patients have been
described earlier.2 Baseline characteristics are shown in Table
1. In brief, between 6 months and up to 2 years after stent
implantation, no additional clinical events occurred. Com-
plete sets of postprocedural, 6-month, and late follow-up
cardiac catheterizations were obtained in 10 of 14 surviving
patients. Four asymptomatic patients refused to undergo a
second diagnostic investigation for scientific purposes only.
At 18 months after the procedure, 1 patient demonstrated a
significant stenosis (60% diameter stenosis; fractional flow
reserve 0.65) located distally to the sirolimus stent (8 mm
from distal edge by quantitative IVUS) that was treated by
direct stenting. Another patient presented with effort angina
22 months after the index procedure and underwent stenting
because of progression of a preexisting atherosclerotic lesion
12 mm from the distal edge of the sirolimus stent (minimal
lumen area by IVUS 3.5 mm2 after the procedure and 3.0 mm2
at 22-month follow-up). Volumetric IVUS measurements
showed no neointimal hyperplasia (NIH) in the stented
segment. Lumen volume of both 5-mm proximal and distal
edges of the sirolimus stent revealed virtually no changes
when comparing postprocedural, 6-month, and 22-month
follow-up measurements.
At almost 2 years of follow-up, 1 death (noncardiac) and 1
target-lesion revascularization occurred, both of which were
in the early in-hospital period (Table 2).
Quantitative Coronary Angiography and
IVUS Analysis
Quantitative coronary angiography data are shown in Table 3.
Twenty-month in-stent minimum lumen diameter
(2.740.41 mm) and percent DS (313%) remained un-
changed compared with 6-month follow-up data
TABLE 1. Baseline Characteristics
Male 10
Age, y 60.214.3 (35–80)
Unstable angina 9
Treated vessel
LAD 6
CX 5
RCA 4
No. of diseased vessels
1 13
2 2
Catheterization follow-up period, mo 20.32.4 (18–24)
Clinical follow-up period, mo 23.31.0 (22–25)
Values are n or meanSD (range). n15.
LAD indicates left anterior descending artery; CX, circumflex artery; and
RCA, right coronary artery.
TABLE 2. Major Adverse Cardiac Events
6 Months 6 to 24 Months Up to 24 Months
Death 1† 0 1
MI* 1 0 1
TLR* 1 0 1
TVR 0 2 2
CABG 0 0 0
n15.
MI indicates myocardial infarction; TLR, target-lesion revascularization; TVR,
target-vessel revascularization; and CABG, coronary artery bypass graft.
*The same patient (periprocedural MI).
†Due to cerebral hemorrhage in hospital.
TABLE 3. Quantitative Coronary Angiography Analysis
Before
Procedure
After Procedure 6-Month Follow-Up 20-Month Follow-Up
In Lesion In Stent In Lesion In Stent In Lesion In Stent
RD, mm 2.970.51 3.010.43 3.020.38 2.850.40
MLD, mm 0.810.24 2.580.43 2.900.33 2.320.37 2.690.30 2.500.51 2.740.41
Stenosis, % 728 1410 1.57 237 118 1215 313
Late loss, mm 0.250.31 0.250.28 0.080.46* 0.200.24*
Late loss index 0.130.20 0.120.11 0.020.30* 0.100.13*
Values are meanSD. n10.
RD indicates reference diameter; MLD, minimal lumen diameter.
*PNS (6-month vs 20-month follow-up). PNS between groups (after procedure, 6-month, and 20-month follow-up). Comparison
by ANOVA.
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(2.690.30 mm and 118%, respectively; PNS). Repre-
sentative sequences of angiograms from a single patient are
shown in Figure 1.
IVUS analysis demonstrated persistent inhibition of NIH at
long-term follow-up (Table 4). FIM study data from Sao
Paulo cohort are also shown in Table 4. Between the 6- and
20-month follow-ups, a small change in NIH (1.41.6 mm3
and 5.95.3 mm3, respectively) and in percent volume
obstruction of the stent (1.11.2% and 4.43.1%, respec-
tively) was observed. Only 1 patient reached 10% NIH of
stent volume as shown by IVUS, which corresponded with an
actual luminal loss of 0.29 mm at the 18-month follow-up
(Figure 1). In addition, no significant change in lumen or
vessel volume was observed in either proximal or distal edges
of the stent (Figure 2). No late stent malapposition was
detected.
Discussion
First clinical applications of sirolimus-eluting stents in de
novo lesions were shown to be safe and feasible in preventing
NIH at 6 months and 1 year, with a complete abolition of
restenosis.1–3 Such findings have provoked considerable in-
terest but have also raised concerns about the long-term
follow-up10,11
In the present study, NIH assessed by IVUS at both 6 and
20 months was not substantially different from the 12-month
follow-up data presented by Sousa et al3 (Table 3). In
addition, the percent volume obstruction of the stent detected
by volumetric IVUS in our study (4.4%) at 20-month
follow-up is importantly less than those observed at 6-month
follow-up in other trials (36% and 25%) using uncoated
stents.12,13 Similarly, in-stent late loss and late loss index
(LLI; 0.20 mm and 0.10, respectively) at a 20-month
follow-up is markedly lower than with bare metal stents, in
which late loss averages were 1.04 to 0.61 mm (LLI 0.59 to
0.39) at a 6-month12,13 and 0.46 mm (LLI 0.30) at a 36-month
follow-up.14 Therefore, our findings provide considerable
reassurance with regard to persistent inhibition of late reste-
nosis or rebound hyperplasia, such as was previously ob-
served with radioactive stents.8
In fact, minimal hyperplasia in humans up to 2 years after
the procedure constitutes the first evidence that behavior in
humans is at variance with the porcine model, where 90-day
data actually demonstrate the recurrence of considerable NIH
(Andrew J. Carter, unpublished data). For the first time in
interventional cardiology, a new antirestenosis therapy per-
forms better in humans than in the animal models.
Concern about potential late complications, such as late
occlusion, thrombosis, late malapposition, aneurysm, and
edge restenosis as reported in patients treated with brachy-
therapy,13 has not been observed in our patient population
during up to 2 years of follow-up.
It has to be emphasized that short-term (8-week) antiplate-
let therapy as used here and in the RAndomized study with
the sirolimus-eluting Bx VELocity balloon-expandable stent
(RAVEL)15 provides adequate protection against subacute
and late thrombotic occlusion. Nonetheless, generalization of
these findings to treatment of long and complex lesions, total
chronic occlusion, left main stem, etc, needs to be specifically
evaluated in clinical trials.
Figure 1. A 38-year-old male with unstable angina
and mid-right coronary artery lesion (arrow) treated
with sirolimus-eluting Bx-velocity stent. No lumen
deterioration was observed at 6- and 18-month
follow-up (6M and 18M). Longitudinal IVUS recon-
structions demonstrate absence of NIH at 6-month
follow-up (B), with minimal NIH (C, arrows) at 18
months compared with after the procedure (A).
TABLE 4. Volumetric IVUS Measurements
Rotterdam
(n10)
Sao Paulo
(n14)*
Follow-up period, mo 6 20 4 12
Stent volume 13331 13229 13821 12730
Lumen volume 13231 12628 13722 12430
NIH volume 1.41.6 5.95.3† 0.30.9 2.53.4
% Volume obstruction 1.11.2 4.43.1† 0.30.8 2.23.4
*Data from Sao Paulo3 (slow-release formulation stent group).
†P0.05, 6-month vs 20-month follow-up.
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The need for late target-vessel revascularization in 2
patients in lesions remote from the sirolimus stent again
emphasizes the indolent nature of atherosclerosis in some
patients. Although this study confirms that sirolimus-eluting
stents constitute a major advance in restenosis prevention, the
problem of atherosclerosis itself remains a considerable
challenge.
Limitations
This is a small observational study and the results need to be
confirmed by long-term follow-up in larger patient series.
Lack of complete QCA and IVUS follow-up was unfortunate
but was not prespecified in the study protocol. The virtual
absence of NIH in the 10 patients studied at 20 months
renders the data quite compelling because the remaining 4
patients were completely asymptomatic.
Conclusion
Sirolimus-eluting Bx-Velocity stents demonstrated persistent
inhibition of neointimal hyperplasia and absence of restenosis
in single de novo coronary lesions for up to 2 years of
follow-up.
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Figure 2. Changes in vessel, plaque, and lumen volume at the
sirolimus-eluting stent (A) and peri-stent margins (5-mm proxi-
mal and 5-mm distal edges of the stent) (B). Individual data are
presented in relation to the line of identity. PNS for 6-month
versus 20-month follow-up
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